Lipertance (Amlodipine Besilate, Perindopril Arginine, Atorvastatin Calcium Trihydrate)

Lipertance combines three agents that act on blood pressure regulation and lipid metabolism, providing therapeutic benefit in several cardiovascular conditions.

• Hypertension: lowers systolic and diastolic pressure through calcium‑channel blockade and ACE inhibition.
• Hyperlipidemia: reduces LDL‑cholesterol and total cholesterol by inhibiting HMG‑CoA reductase.
• Cardiovascular risk reduction: decreases the likelihood of major adverse cardiac events by simultaneously controlling blood pressure and lipid levels.

• Amlodipine besilate binds to L‑type calcium channels on vascular smooth muscle, causing vasodilation. Perindopril arginine inhibits angiotensin‑converting enzyme, lowering angiotensin II production and reducing vasoconstriction. Atorvastatin calcium trihydrate competitively inhibits HMG‑CoA reductase, the rate‑limiting enzyme in hepatic cholesterol synthesis, leading to up‑regulation of LDL receptors and decreased circulating LDL‑cholesterol. Together, the agents address two major modifiable risk factors for atherosclerotic disease.

Lipertance may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Headache: mild to moderate headache reported.
• Peripheral edema: swelling of ankles or feet.
• Dizziness: transient light‑headedness.
• Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects

• Angioedema: swelling of face, lips, or airway.
• Hepatotoxicity: elevated liver enzymes or hepatitis.
• Rhabdomyolysis: muscle pain with CK elevation, especially with the statin component.

When prescribing Lipertance, clinicians should consider several safety measures to minimize risk.

• Monitor blood pressure: check regularly after initiation and dose changes.
• Assess renal function: adjust therapy in severe renal impairment.
• Check liver enzymes: baseline and periodic monitoring due to statin component.
• Evaluate for pregnancy: avoid use unless benefits outweigh risks.
• Review concomitant medications: consider potential drug interactions.
• Store at room temperature: keep in original container, protect from moisture and light.

Lipertance can interact with other medicines; some combinations require avoidance while others need careful monitoring.

Major Interactions (Avoid)

• ACE inhibitor with potassium‑sparing diuretics or supplements: risk of hyperkalaemia.
• Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): increase atorvastatin exposure, risk of rhabdomyolysis.
• Concomitant use of other calcium‑channel blockers: additive hypotensive effect.

Moderate Interactions (Monitor Closely)

• NSAIDs: may blunt antihypertensive effect.
• Antacids containing aluminium or magnesium: may reduce absorption of perindopril.
• Fibrates (e.g., gemfibrozil): increase risk of statin‑related muscle toxicity.